Andrea Sylvester, NP
Nurse Practitioner · Ludington, MINPI 1942608005
Payments from drug & device makers
Across 75 payments — averaging $33.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$446
- Acadia Pharmaceuticals Inc$196
- Sunovion Pharmaceuticals Inc.$188
- Jazz Pharmaceuticals Inc.$184
- Novo Nordisk$166
- Amgen$157
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $446 |
| Acadia Pharmaceuticals Inc | 4 | $196 |
| Sunovion Pharmaceuticals Inc. | 2 | $188 |
| Jazz Pharmaceuticals Inc. | 2 | $184 |
| Novo Nordisk | 7 | $166 |
| Amgen | 3 | $157 |
| AstraZeneca | 3 | $148 |
| Johnson & Johnson | 3 | $133 |
| Bayer | 3 | $133 |
| Boehringer Ingelheim | 3 | $125 |
| Astellas Pharma US Inc | 3 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| CMP Pharma, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,531 in reported general payments places this provider in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 203 | $129,562 |
| TrulicityDulaglutide | 48 | $47,972 |
| XareltoRivaroxaban | 74 | $43,616 |
| MyrbetriqMirabegron | 75 | $36,303 |
| VraylarCariprazine Hcl | 19 | $25,925 |
| JardianceEmpagliflozin | 31 | $18,973 |
| RexultiBrexpiprazole | 18 | $18,235 |
| Spiriva HandihalerTiotropium Bromide | 27 | $15,218 |
| LinzessLinaclotide | 25 | $13,819 |
| Humalog Kwikpen U-100Insulin Lispro | 126 | $12,906 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $11,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,481 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $11,468 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 146 | $10,998 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $10,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $129,562203 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $33 | $52,434352 claims |
| Johnson & JohnsonXarelto | $133 | $43,61674 claims |
| AbbVieVraylar, Linzess | $446 | $39,74444 claims |
| Astellas Pharma US IncMyrbetriq | $117 | $36,30375 claims |
| Boehringer IngelheimJardiance | $125 | $18,97331 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $38 | $18,23518 claims |
| AstraZenecaSymbicort | $148 | $9,17335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Ludington
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.